US public health group attacks safety of GSKs asthma drug

Warning message

This news item is more than a year old. Links, graphics, content, medical information, and statistics may be out of date. We invite you to search, visit our homepage, or contact us to find more current information on the topic you're looking for.


US  public health group attacks safety of GSK's asthma drug

By Stephen Foley, The Independent
Published: 07 October 2005

An American consumer campaign group claims GSK manipulated results of a 26,000-patient study of its asthma treatment Serevent, which is known as Advair when in combination with another drug.

GSK's response is also published by The Lancet, and the drug company moved yesterday to limit the damage, saying that the claims were false, and it had acted transparently and in good faith while the 26,000-patient "Smart" trial data was being fully understood.

Full story

The Lancet articles (registration required)
Misleading data analyses in salmeterol (SMART) study

Misleading data analyses in salmeterol (SMART) study -GlaxoSmithKline's reply

More information on asthma and asthma education  


AddThis Social Sharing Icon

Page Last Updated: 01/12/2017